Medscape is available in 5 Language Editions – Choose your Edition here.


Intestinal Polyposis Syndromes Treatment & Management

  • Author: Evelyn K Hsu, MD; Chief Editor: Carmen Cuffari, MD  more...
Updated: Jul 21, 2015

Medical Care

In several of the polyposis syndromes, medical care encompasses screening and intervention for malignant transformation. Particularly in the case of familial adenomatous polyposis (FAP), in which an inevitable progression to colorectal cancer occurs by age 35-40 years,[22] screening of patients and family members has led to an improvement in cumulative survival and a 55% reduction in colorectal cancer at diagnosis of FAP.[56] Approximately 50% of patients with familial juvenile polyposis (FJP) develop GI cancer.[57]

Familial adenomatous polyposis

Unless a family history of early and aggressive disease is noted, children at risk for FAP should be screened twice yearly starting at age 10-12 years. Flexible sigmoidoscopy is sufficient because the adenomas are distributed throughout the colon. The American Gastroenterological Association recommends an annual sigmoidoscopy or colonoscopy for patients with a genetic diagnosis of FAP or for at-risk family members who have not undergone genetic testing.[58] Narrow-band imaging can identify higher numbers of duodenal adenomas, but it did not lead to a clinically relevant upgrade in stage when compared with high-resolution endoscopy.[59]

If the patient undergoes prophylactic colectomy, the ileal pouch is at risk for developing adenomatous carcinoma and should be screened with endoscopy on a yearly basis. Gastric and duodenal lesions occur in 45% of patients with the APC mutation, and upper endoscopy should begin when colonic adenomas are identified or at age 20-25 years. A study of pediatric patients with APC mutations suggests that upper endoscopy should begin even earlier.[60]

The risk of developing malignancy in these lesions is lower than the risk from colonic lesions. Depending on the polyp burden, front and/or side-viewing endoscopies of the stomach, duodenum, and periampullary region should occur every 6 months to 4 years. The risk of periampullary tumors is increased in these patients. The tumors are best viewed with both side-viewing and end-viewing instruments.[61]

Patients with the APC gene mutation at codon 1309 are at risk for a more aggressive phenotype, and early screening and colectomy is advocated for in children with this mutation.[60]

Postcolectomy, mesenteric or abdominal wall desmoids can develop and may cause fatal complications from sepsis or hemorrhage. They are more common in females and can cause obstruction of the mesenteric blood supply, intestines, or urinary tract.[4]

Gardner syndrome

In addition to the above recommendations for FAP, patients with Gardner syndrome require medical care and management of cutaneous cysts, osteomas, fibromas, polyposis, and diligent surveillance for neoplasia.

Carcinoma may develop at any age, from late childhood through senior years.

Young children with gene mutations related to Gardner syndrome have an increased risk for development of hepatoblastoma. Hughes and Michels noted Gardner syndrome in 2 of 470 children who had parents with Gardner syndrome versus an incidence of 1 per 100,000 general population.[62]

Patients with Gardner syndrome are predisposed to the development of polyposis throughout the GI tract and to carcinomas of the stomach, periampullary region, biliary tract, and colon.

Women with Gardner syndrome have an increased risk of desmoid tumors and thyroid carcinoma.

Development of thyroid carcinoma is 100 times more likely among patients with Gardner syndrome.

Osteosarcomas and adrenal carcinomas (with Cushing syndrome) have been previously reported in patients with Gardner syndrome.

Turcot syndrome

As with Gardner syndrome, in addition to the above recommendations for FAP, patients with Turcot syndrome require management of basal cell carcinomas and treatment of CNS malignancies, including astrocytoma, glioblastoma, and medulloblastoma.

Patients with Turcot syndrome are predisposed to the development of hepatic focal nodular hyperplasia.

Peutz-Jeghers syndrome

Patients require medical management for problems attributed to polyposis and for detection of malignancy.

Patients with Peutz-Jeghers syndrome (PJS) may develop significant GI bleeding, intussusception, and rectal prolapse, requiring diagnosis and treatment, including endoscopy and surgical resection.

Nasal endoscopy may be necessary in the presence of chronic sinusitis to exclude the presence of significant nasal polyps.

Long-term surveillance strategies to monitor for GI malignancies, including bowel, pancreatic, and periampullary malignancies. Colonoscopy is recommended every 3 years starting when symptoms occur or in the early teenage years in asymptomatic patients. At age 10 years, twice yearly upper endoscopies and barium imaging of the upper GI tract are recommended.[61]

Long-term surveillance to monitor for extraintestinal malignancies (eg, breast, gynecologic, testicular) is indicated.

The use of the potassium titanyl phosphate (KTP) laser to treat mucocutaneous melanosis of the lips and hands in a patient with PJS has been reported in the United Kingdom.

PTEN-hamartomatous syndromes

Patients require medical therapy for CNS abnormalities, complications of lipomas and arteriovenous malformations, treatment of Hashimoto thyroiditis, and surveillance for malignancy.

Children may exhibit hypotonia, developmental delay, and mild mental retardation that requires coordinated speech and occupational and physical therapies to maximize potential.

Significant lipomatous or vascular lesions (hemangiomas, arteriovenous malformations) have resulted in CNS complications (eg, seizures), amputations, and premature death.

Patients appear to have an increased risk for CNS tumors.

Increased incidence of Hashimoto thyroiditis, along with abnormalities of the PTEN gene (tumor suppressor gene), enhance the likelihood for development of neoplasia, especially thyroid and breast.

Patients require careful monitoring for the development of malignancies within the cerebellum, breast, skin (Merkel cell), and kidneys (renal cell adenocarcinoma).

Gorlin syndrome

Patients may require medical attention for craniofacial, vertebral, dental, and ophthalmologic abnormalities, in addition to diagnosis and treatment of potential neoplasia.

Bale reported that 3% of patients with Gorlin syndrome (GS) presented with cleft lip and palate at birth.[50]

Scoliosis is commonly associated with GS.

Jaw cysts are noted in more than 50% of patients, accompanied by symptoms of optic nerve compression, abnormalities of taste, and facial paresthesias.

Fibrosarcomas of the jaw have been encountered in patients with GS.

Glaucoma and cataracts have been described in patients with GS.

Patients with GS are predisposed to the development of neoplasia of the CNS, skin, and reproductive organs.

In childhood, medulloblastomas have been reported in 5% of patients with GS.

Basal cell carcinomas may present in patients younger than 10 years, especially with prior history of exposure to ionizing radiation. Nearly all patients with GS develop basal cell carcinomas by the fourth decade of life.

Individuals with GS may present with abdominal symptoms that arise from abnormalities of the GI (lymphatic, mesenteric cysts) and gynecologic systems. Young girls with GS may develop ovarian fibromas (predisposed to torsion) and fibrosarcomas. Khalifa et al reported endometrial adenocarcinoma in a 37-year-old woman with GS.

Familial juvenile polyposis

Esophagogastroduodenoscopy (EGD) and colonoscopy should be performed at age of onset of symptoms or at age 15 years in asymptomatic patients at risk. If no polyps are present, this should be repeated every 3 years. If polyps are seen, they should be removed and EGD and colonoscopy should be performed yearly until no polyps are seen.[63]

Cronkhite-Canada syndrome

Patients should be regularly screened for colorectal and gastric cancer because they are at higher risk of developing malignancy in these areas.


Surgical Care

Familial adenomatous polyposis

The inevitable course is the development of colorectal cancer. To prevent this, surgical intervention is required, in the form of total proctocolectomy with ileoanal anastomosis, subtotal colectomy with ileorectal anastomosis, or total proctocolectomy with permanent ileostomy.

In patients who have subtotal colectomy with ileorectal anastomosis, the remaining rectal stump must be monitored for polyp recurrence. Timing of prophylactic colectomy or proctocolectomy has not been standardized, with most authors recommending that once polyposis is confirmed, severely affected patients should have prophylactic surgery as soon as possible. Mildly affected patients are recommended to have surgery within the year.[64]

Patients with Gardner syndrome require surgical treatment of the following:

  • Cutaneous cysts
  • Symptomatic dental anomalies and osteomas
  • Biopsy and resection for malignancies, including hepatoblastoma, thyroid carcinoma, osteocarcinoma, gastric carcinoma, periampullary carcinoma, and biliary tract carcinoma
  • Liver transplantation may be required in patients with hepatoblastoma

Patients with Turcot syndrome require surgical intervention for diagnosis and management of CNS lesions, gastric lesions and hepatic lesions.

Peutz-Jeghers syndrome

Patients may require surgical intervention for symptomatic GI lesions and biopsy of suspicious areas to exclude the possibility of malignancy.

Some patients with PJS develop manifestations of short-bowel syndrome secondary to long-term resections for potential malignancies (ie, antrectomy, duodenectomy).

PTEN-hamartomatous syndromes

Patients may require surgical intervention for management of serious lipomatous, vascular lesions, and undescended testicles and biopsy of suggestive areas to exclude the possibility of occult malignancy.

Later in age, these patients may require surgical intervention for management of symptomatic polyposis, scoliosis, and increased intracranial pressure

Biopsy and resection of lesions within the cerebellum (dysplastic gangliocytomas), breast, and kidneys (renal cell adenocarcinoma) may be required.

Consideration of prophylactic mastectomy is recommended for women

Gorlin syndrome

Patients with GS may require surgical management for the following:

  • Craniofacial lesions (cleft lip and palate, jaw cysts, other mandibular lesions)
  • Abdominal masses (mesenteric cysts, lymphatic cysts, ovarian fibromas)
  • Diagnostic and therapeutic interventions for potential neoplasia within the CNS (medulloblastoma), skin (basal cell carcinoma), jaw (fibrosarcoma), ovaries (fibrosarcoma), and endometrium (adenocarcinoma)

Familial juvenile polyposis

With the cumulative risk of malignancy greater than 50%, no guidelines have been established; however, some authors are recommending subtotal colectomy with ileorectal anastomosis in children with anemia, hypoproteinemia, and failure to thrive.[65]

Prophylactic colectomy with ileorectal anastomosis is recommended for children who have severe or repeated bleeding and adults with FJP.[66]



Familial adenomatous polyposis

Patients with Gardner syndrome may require consultation with the following:

  • Gastroenterologist - For monitoring and surveillance for malignancies
  • Oncologist - For treatment of malignancies
  • Surgeon - For biopsy or resection of suspicious areas
  • Dentist or maxillofacial surgeon - For mandibular osteomas or dental anomalies
  • Ophthalmologist - For evaluation for retinal anomalies
  • Endocrinologist - For evaluation and management of thyroid carcinoma and adrenal carcinoma

Patients with Turcot syndrome may require medical consultation with the following:

  • Gastroenterologist - For monitoring and surveillance for malignancies
  • Oncologist - For monitoring and treatment of malignancies
  • Dermatologist
  • Surgeon - For management of CNS, cutaneous, and GI malignancies

Peutz-Jeghers syndrome

Patients with PJS may require consultation with the following:

  • Gastroenterologist: Assistance from a gastroenterologist may localize sites of polyps or bleeding.
  • Surgeon: Surgical intervention may include resection of symptomatic areas and biopsy for suspicious malignancy.
  • Dermatologist: Some patients with PJS may initially present to the dermatologist for diagnosis of cutaneous lesions.
  • Endocrinologist
  • Gynecologist
  • Urologist
  • Otolaryngologist
  • Oncologist: An oncologist directs appropriate therapy in the presence of intestinal or extraintestinal malignancy.

PTEN-hamartomatous syndromes

Patients with BRR may require consultation with the following:

  • Dermatologist
  • Developmental pediatrician: The developmental pediatrician manages seizures and develops strategies for neurodevelopmental stimulation.
  • Endocrinologist: An endocrinologist treats Hashimoto thyroiditis and cryptorchidism.
  • Gastroenterologist: A gastroenterologist evaluates for polyposis, manages symptoms of drooling, and establishes GI surveillance.
  • Gynecologist: A gynecologist establishes surveillance strategies for breast neoplasia.
  • Neurologist: The neurologist manages seizures and develops strategies for neurodevelopmental stimulation.
  • Oncologist: An oncologist directs appropriate therapy if malignant transformation occurs.
  • Surgeon: Consultation with a surgeon is indicated for treatment of increased intracranial pressure, cerebellar lesions, breast cancer, thyroid lesions, and renal carcinoma.

Gorlin syndrome

Patients with GS may require subspecialty support for treatment of craniofacial and ophthalmologic abnormalities, management of scoliosis, and surveillance and treatment of potential neoplasias (eg, medulloblastoma, basal cell carcinoma, ovarian fibromas and sarcomas, mesenteric cysts).



The benefits of low-fat/high-fiber diets and supplementation with either calcium or antioxidants, including ascorbic acid and alpha-tocopherol, is controversial in patients with FAP. Several controlled trials in adults have studied dietary interventions, including wheat bran, vitamin intake, and fiber on the rate of development of adenomatous polyps.[67]

Yang et al noted a decrease in colonic epithelial proliferation activity via increasing calcium intake to 1200 mg with low-fat dairy foods;[68] however, the Toronto polyp prevention trial found no difference in the incidence of polyp recurrence between a low-fat/high-fiber diet and a typical Western diet with placebo fiber.[69] Fuchs et al also noted no protective effect of dietary fiber against colorectal adenomas and carcinoma in women.[70]

No studies are currently available regarding dietary modification in patients with PJS. Development of short-bowel syndrome from repetitive intestinal resections requires special nutritional interventions, including vitamin and nutrient supplementation, continuous enteral feedings, or parenteral nutrition.

No studies are currently available regarding dietary modification in patients with PTEN -hamartomatous syndromes or GS.



No limitation of activity is mandated for patients with PJS, BRR, Gardner syndrome, or Turcot syndrome unless other medical issues necessitate restrictions.

Patients with GS should minimize exposure to ultraviolet light and ionizing radiation to reduce the risk of developing basal cell carcinomas.

No limitation of physical activity is mandated for patients with Cowden disease unless other physical conditions are present. Patients with Cowden disease have an increased risk for development of thyroid carcinoma and may wish to minimize exposure of the neck to ionizing radiation.

Contributor Information and Disclosures

Evelyn K Hsu, MD Assistant Professor of Pediatrics, Division of Gastroenterology and Hepatology, Seattle Children's Hospital

Evelyn K Hsu, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American Gastroenterological Association, American Society of Transplantation, North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, International Pediatric Transplant Association

Disclosure: Received grant/research funds from Roche for investigator.


Petar Mamula, MD Associate Professor, Department of Pediatrics, Division of Gastroenterology and Nutrition, The Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine

Petar Mamula, MD is a member of the following medical societies: American Academy of Pediatrics, American Society for Gastrointestinal Endoscopy, American Gastroenterological Association, North American Society for Pediatric Gastroenterology, Hepatology and Nutrition

Disclosure: Nothing to disclose.

Eduardo D Ruchelli, MD Associate Professor of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine; Attending Physician, Department of Pathology, Children’s Hospital of Philadelphia

Eduardo D Ruchelli, MD is a member of the following medical societies: United States and Canadian Academy of Pathology, Society for Pediatric Pathology

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Stefano Guandalini, MD Founder and Medical Director, Celiac Disease Center, Chief, Section of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, University of Chicago Medical Center; Professor, Department of Pediatrics, Section of Gastroenterology, Hepatology and Nutrition, University of Chicago Division of the Biological Sciences, The Pritzker School of Medicine

Stefano Guandalini, MD is a member of the following medical societies: American Gastroenterological Association, North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, European Society for Paediatric Gastroenterology, Hepatology & Nutrition, North American Society for the Study of Celiac Disease

Disclosure: Received consulting fee from AbbVie for consulting.

Chief Editor

Carmen Cuffari, MD Associate Professor, Department of Pediatrics, Division of Gastroenterology/Nutrition, Johns Hopkins University School of Medicine

Carmen Cuffari, MD is a member of the following medical societies: American College of Gastroenterology, American Gastroenterological Association, North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, Royal College of Physicians and Surgeons of Canada

Disclosure: Received honoraria from Prometheus Laboratories for speaking and teaching; Received honoraria from Abbott Nutritionals for speaking and teaching.

Additional Contributors

Jayant Deodhar, MD Associate Professor in Pediatrics, BJ Medical College, India; Honorary Consultant, Departments of Pediatrics and Neonatology, King Edward Memorial Hospital, India

Disclosure: Nothing to disclose.


Ann Scheimann, MD, MBA Associate Professor, Department of Pediatrics, Section of Nutrition and Gastroenterology, Baylor College of Medicine and Johns Hopkins Medical Institution

Ann Scheimann, MD, MBA is a member of the following medical societies: North American Society for Pediatric Gastroenterology and Nutrition

Disclosure: Nothing to disclose.

  1. Chargelaigue A. Des Polypes du Rectum. Thesis Paris. 1859.

  2. Turcot J, Despres JP, St Pierre F. Malignant tumors of the central nervous system associated with familial polyposis of the colon: report of two cases. Dis Colon Rectum. 1959 Sep-Oct. 2:465-8. [Medline].

  3. Baughman FA, List CF, Williams JR, et al. The glioma-polyposis syndrome. New England Journal of Medicine. 1969. 281:1345-46. [Medline].

  4. Erdman SH. Pediatric adenomatous polyposis syndromes: an update. Curr Gastroenterol Rep. 2007 Jun. 9(3):237-44. [Medline].

  5. Peutz J. Very remarkable case of familial polyposis of mucous membrane of intestinal tract and nasopharynx accompanied by peculiar pigmentations of skin and mucous membrane. Nederl Maandschr Geneesk. 1921. 10:1921.

  6. Jeghers H, McKusick VA, Katz KH. Generalized intestinal polyposis and melanin spots of the oral mucosa, lips and digits; a syndrome of diagnostic significance. N Engl J Med. 1949 Dec 22. 241(25):993, illust; passim. [Medline].

  7. Lloyd KM 2nd, Dennis M. Cowden's disease. A possible new symptom complex with multiple system involvement. Ann Intern Med. 1963 Jan. 58:136-42. [Medline].

  8. Weary PE, Gorlin RJ, Gentry WC Jr, Comer JE, Greer KE. Multiple hamartoma syndrome (Cowden's disease). Arch Dermatol. 1972 Nov. 106(5):682-90. [Medline].

  9. Padberg GW, Schot JD, Vielvoye GJ, Bots GT, de Beer FC. Lhermitte-Duclos disease and Cowden disease: a single phakomatosis. Ann Neurol. 1991 May. 29(5):517-23. [Medline].

  10. HD Riley WS. Macrocephaly, pseudopapilledema and multiple hemangiomata: a previously undescribed heredofamilial syndrome. Pediatrics. 1960. 26:293-300.

  11. Bannayan GA. Lipomatosis, angiomatosis, and macrencephalia. A previously undescribed congenital syndrome. Arch Pathol. 1971 Jul. 92(1):1-5. [Medline].

  12. Lachlan KL, Lucassen AM, Bunyan D, Temple IK. Cowden syndrome and Bannayan Riley Ruvalcaba syndrome represent one condition with variable expression and age-related penetrance: results of a clinical study of PTEN mutation carriers. J Med Genet. 2007 Sep. 44(9):579-85. [Medline].

  13. Calva D, Howe JR. Hamartomatous polyposis syndromes. Surg Clin North Am. 2008 Aug. 88(4):779-817, vii. [Medline]. [Full Text].

  14. Gorlin RJ. Nevoid basal-cell carcinoma syndrome. Medicine (Baltimore). 1987 Mar. 66(2):98-113. [Medline].

  15. Hamilton SR, Liu B, Parsons RE, Papadopoulos N, Jen J, Powell SM. The molecular basis of Turcot's syndrome. N Engl J Med. 1995 Mar 30. 332(13):839-47. [Medline].

  16. Tops CM, Vasen HF, van Berge Henegouwen G, et al. Genetic evidence that Turcot syndrome is not allelic to familial adenomatous polyposis. Am J Med Genet. 1992 Jul 15. 43(5):888-93. [Medline].

  17. Hemminki A, Markie D, Tomlinson I, et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature. 1998 Jan 8. 391(6663):184-7. [Medline].

  18. Jenne DE, Reimann H, Nezu J, et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet. 1998 Jan. 18(1):38-43. [Medline].

  19. Volikos E, Robinson J, Aittomäki K, Mecklin JP, Järvinen H, Westerman AM. LKB1 exonic and whole gene deletions are a common cause of Peutz-Jeghers syndrome. J Med Genet. 2006 May. 43(5):e18. [Medline]. [Full Text].

  20. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A. 1999 Feb 16. 96(4):1563-8. [Medline].

  21. Jones KL, Smith DW, Harvey MA, Hall BD, Quan L. Older paternal age and fresh gene mutation: data on additional disorders. J Pediatr. 1975 Jan. 86(1):84-8. [Medline].

  22. Bisgaard ML, Fenger K, Bülow S, Niebuhr E, Mohr J. Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. Hum Mutat. 1994. 3(2):121-5. [Medline].

  23. Paraf F, Jothy S, Van Meir EG. Brain tumor-polyposis syndrome: two genetic diseases?. J Clin Oncol. 1997 Jul. 15(7):2744-58. [Medline].

  24. Krush AJ, Giardiello FM. Development of a genetics registry: Hereditary intestinal polyposis and hereditary colon cancer registry at the Johns Hopkins Hospital, 1973-1988. Herrera L. Familial Adenomatous Polyposis. New York, NY: Alan R. Liss Inc; 1990.

  25. Farndon PA, Del Mastro RG, Evans DG, Kilpatrick MW. Location of gene for Gorlin syndrome. Lancet. 1992 Mar 7. 339(8793):581-2. [Medline].

  26. Burn J, Chapman P, Delhanty J, Wood C, Lalloo F, Cachon-Gonzalez MB. The UK Northern region genetic register for familial adenomatous polyposis coli: use of age of onset, congenital hypertrophy of the retinal pigment epithelium, and DNA markers in risk calculations. J Med Genet. 1991 May. 28(5):289-96. [Medline].

  27. Rustgi AK. The genetics of hereditary colon cancer. Genes Dev. 2007 Oct 15. 21(20):2525-38. [Medline].

  28. Nelen MR, Kremer H, Konings IB, Schoute F, van Essen AJ, Koch R. Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. Eur J Hum Genet. 1999 Apr. 7(3):267-73. [Medline].

  29. Van Meir EG. "Turcot's syndrome": phenotype of brain tumors, survival and mode of inheritance. Int J Cancer. 1998 Jan 5. 75(1):162-4. [Medline].

  30. Giardiello FM, Brensinger JD, Petersen GM. AGA technical review on hereditary colorectal cancer and genetic testing. Gastroenterology. 2001 Jul. 121(1):198-213. [Medline].

  31. Kimonis VE, Goldstein AM, Pastakia B, Yang ML, Kase R, DiGiovanna JJ. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet. 1997 Mar 31. 69(3):299-308. [Medline].

  32. Klemmer S, Pascoe L, DeCosse J. Occurrence of desmoids in patients with familial adenomatous polyposis of the colon. Am J Med Genet. 1987 Oct. 28(2):385-92. [Medline].

  33. Bell B, Mazzaferri EL. Familial adenomatous polyposis (Gardner's syndrome) and thyroid carcinoma. A case report and review of the literature. Dig Dis Sci. 1993 Jan. 38(1):185-90. [Medline].

  34. Hanssen AM, Fryns JP. Cowden syndrome. J Med Genet. 1995 Feb. 32(2):117-9. [Medline].

  35. Distante S, Nasioulas S, Somers GR, Cameron DJ, Young MA, Forrest SM. Familial adenomatous polyposis in a 5 year old child: a clinical, pathological, and molecular genetic study. J Med Genet. 1996 Feb. 33(2):157-60. [Medline].

  36. Fernandez Seara MJ, Martinez Soto MI, Fernandez Lorenzo JR, Trabazo S, Gamborino E, Forteza Vila J. Peutz-Jeghers syndrome in a neonate. J Pediatr. 1995 Jun. 126(6):965-7. [Medline].

  37. Blumenthal GM, Dennis PA. PTEN hamartoma tumor syndromes. Eur J Hum Genet. 2008 Nov. 16(11):1289-300. [Medline].

  38. Cohen S, Gorodnichenco A, Weiss B, et al. Polyposis syndromes in children and adolescents: a case series data analysis. Eur J Gastroenterol Hepatol. 2014 Sep. 26 (9):972-7. [Medline].

  39. Talbot I. Pathology. Phillips RKS SA, Thompson JPS. Familial Adenomatous Polyposis and Other Polyposis Syndrome. Oxford UP; 1994. 15-35.

  40. Hemminki A. The molecular basis and clinical aspects of Peutz-Jeghers syndrome. Cell Mol Life Sci. 1999 May. 55(5):735-50. [Medline].

  41. Tan WH, Baris HN, Burrows PE, Robson CD, Alomari AI, Mulliken JB. The spectrum of vascular anomalies in patients with PTEN mutations: implications for diagnosis and management. J Med Genet. 2007 Sep. 44(9):594-602. [Medline].

  42. Genevieve D, Walter E, Gorry P, Jacquemont ML, Dupic L, Layet V. Gorlin syndrome presenting as prenatal chylothorax in a girl. Prenat Diagn. 2005 Nov. 25(11):997-9. [Medline].

  43. Sachatello CR, Hahn IS, Carrington CB. Juvenile gastrointestinal polyposis in a female infant: report of a case and review of the literature of a recently recognized syndrome. Surgery. 1974 Jan. 75(1):107-14. [Medline].

  44. Costa AG, Costa RO, Oliveira LR, Grossmann SM. Multiple oral radiopaque masses leading to Gardner's syndrome diagnosis. Gen Dent. 2013 Jul. 61(4):e12-4. [Medline].

  45. Yun SH, Cho JW, Kim JW, Kim JK, Park MS, Lee NE, et al. Cronkhite-Canada syndrome associated with serrated adenoma and malignant polyp: a case report and a literature review of 13 cronkhite-Canada syndrome cases in Korea. Clin Endosc. 2013 May. 46(3):301-5. [Medline]. [Full Text].

  46. Peifer M. Cancer, catenins, and cuticle pattern: a complex connection. Science. 1993 Dec 10. 262(5140):1667-8. [Medline].

  47. Arch EM, Goodman BK, Van Wesep RA, Liaw D, Clarke K, Parsons R. Deletion of PTEN in a patient with Bannayan-Riley-Ruvalcaba syndrome suggests allelism with Cowden disease. Am J Med Genet. 1997 Sep 5. 71(4):489-93. [Medline].

  48. Hahn H, Wicking C, Zaphiropoulous PG, Gailani MR, Shanley S, Chidambaram A. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 1996 Jun 14. 85(6):841-51. [Medline].

  49. Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science. 1996 Jun 14. 272(5268):1668-71. [Medline].

  50. Bale AE. Variable expressivity of patched mutations in flies and humans. Am J Hum Genet. 1997 Jan. 60(1):10-2. [Medline].

  51. Winawer SJ, Zauber AG, Fletcher RH, et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology. 2006 May. 130(6):1872-85. [Medline].

  52. Gorospe EC, Alexander JA, Bruining DH, et al. Performance of double-balloon enteroscopy for the management of small bowel polyps in hamartomatous polyposis syndromes. J Gastroenterol Hepatol. 2013 Feb. 28 (2):268-73. [Medline].

  53. Sidhu R, Sanders DS, McAlindon ME, Thomson M. Capsule endoscopy and enteroscopy: modern modalities to investigate the small bowel in paediatrics. Arch Dis Child. 2008 Feb. 93(2):154-9. [Medline].

  54. de' Angelis GL, Fornaroli F, de' Angelis N, Magiteri B, Bizzarri B. Wireless capsule endoscopy for pediatric small-bowel diseases. Am J Gastroenterol. 2007 Aug. 102(8):1749-57; quiz 1748, 1758. [Medline].

  55. Gruber SB, Entius MM, Petersen GM, et al. Pathogenesis of adenocarcinoma in Peutz-Jeghers syndrome. Cancer Res. 1998 Dec 1. 58(23):5267-70. [Medline].

  56. Bulow S. Results of national registration of familial adenomatous polyposis. Gut. 2003 May. 52(5):742-6. [Medline].

  57. Howe JR, Mitros FA, Summers RW. The risk of gastrointestinal carcinoma in familial juvenile polyposis. Ann Surg Oncol. 1998 Dec. 5(8):751-6. [Medline].

  58. Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology. 2003 Feb. 124(2):544-60. [Medline].

  59. Lopez-Ceron M, van den Broek FJ, Mathus-Vliegen EM, et al. The role of high-resolution endoscopy and narrow-band imaging in the evaluation of upper GI neoplasia in familial adenomatous polyposis. Gastrointest Endosc. 2013 Apr. 77(4):542-50. [Medline].

  60. Attard TM, Cuffari C, Tajouri T, Stoner JA, Eisenberg MT, Yardley JH. Multicenter experience with upper gastrointestinal polyps in pediatric patients with familial adenomatous polyposis. Am J Gastroenterol. 2004 Apr. 99(4):681-6. [Medline].

  61. Barnard J. Screening and surveillance recommendations for pediatric gastrointestinal polyposis syndromes. J Pediatr Gastroenterol Nutr. 2009 Apr. 48 Suppl 2:S75-8. [Medline]. [Full Text].

  62. Hughes LJ, Michels VV. Risk of hepatoblastoma in familial adenomatous polyposis. Am J Med Genet. 1992 Aug 1. 43(6):1023-5. [Medline].

  63. Burt RW. Colon cancer screening. Gastroenterology. 2000 Sep. 119(3):837-53. [Medline].

  64. Church JM, McGannon E, Burke C, Clark B. Teenagers with familial adenomatous polyposis: what is their risk for colorectal cancer?. Dis Colon Rectum. 2002 Jul. 45(7):887-9. [Medline].

  65. Howe JR, Roth S, Ringold JC, et al. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science. 1998 May 15. 280(5366):1086-8. [Medline].

  66. Howe JR, Ringold JC, Hughes JH, Summers RW. Direct genetic testing for Smad4 mutations in patients at risk for juvenile polyposis. Surgery. 1999 Aug. 126(2):162-70. [Medline].

  67. Jänne PA, Mayer RJ. Chemoprevention of colorectal cancer. N Engl J Med. 2000 Jun 29. 342(26):1960-8. [Medline].

  68. Yang K, Yang W, Mariadason J, Velcich A, Lipkin M, Augenlicht L. Dietary components modify gene expression: implications for carcinogenesis. J Nutr. 2005 Nov. 135(11):2710-4. [Medline].

  69. Macrae F. Wheat bran fiber and development of adenomatous polyps: evidence from randomized, controlled clinical trials. Am J Med. 1999 Jan 25. 106(1A):38S-42S. [Medline].

  70. Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Stampfer MJ, Rosner B. Dietary fiber and the risk of colorectal cancer and adenoma in women. N Engl J Med. 1999 Jan 21. 340(3):169-76. [Medline].

  71. Durno CA, Wong J, Berk T, Alingary N, Cohen Z, Esplen MJ. Quality of life and functional outcome for individuals who underwent very early colectomy for familial adenomatous polyposis. Dis Colon Rectum. 2012 Apr. 55(4):436-43. [Medline].

  72. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993 May 6. 328(18):1313-6. [Medline].

Familial adenomatous polyposis, total colectomy specimen. The colonic mucosa is studded with innumerable sessile and small pedunculated polyps, which involve the entire length of the specimen.
Pedunculated tubular adenoma. Note the contrast between the goblet cell-rich glands along the pedicle of the polyp and in the underlying normal colonic mucosa at the bottom and the dysplastic glands in the polyp proper. The dysplastic glands are more crowded and exhibit decreased mucin production. (Hematoxylin and eosin stain; 1X magnification).
Sessile tubular adenoma. The glands on the superficial aspect of the specimen are dysplastic and exhibit increased nuclear size, hyperchromasia, crowding, and decreased mucin production. (Hematoxylin and eosin stain, 4X magnification).
Hamartomatous (Peutz-Jeghers) polyp, small bowel. This pedunculated polyp has a cerebriform appearance due to the arborizing frond-like growth with delicate finger-like projections of the stroma. (Hematoxylin and eosin stain, 1X magnification).
Hamartomatous (Peutz-Jeghers) polyp, small bowel. Closer view of the fingerlike projections of the stroma demonstrates prominent smooth muscle fascicles between the glandular elements. (Hematoxylin and eosin stain, 4X magnification).
Hamartomatous polyp, as seen in the stomach. (Endoscopic image).
Colon in familial adenomatous polyposis (FAP). (Endoscopic image).
Small bowel polyp. (Video capsule image).
Multiple large polyps in the colon. The polyp in the center of the image is situated on a stalk. (Endoscopic image).
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.